CTLA4 and COVID-19: The diminished antibody response to the COVID-19 vaccines is attributed to the well-documented impact of the CTLA-4-Ig and TNF-α inhibitors on reducing the frequency of peripheral memory B cells in humans’ peripheral blood [57].